查詢結果分析
相關文獻
頁籤選單縮合
題 名 | Patient-centered and Integrated Outreach Care for Chronic Hepatitis C Patients with Serious Mental Illness in Taiwan |
---|---|
作 者 | Huang, Chung-feng; Jang, Tyng-yuan; Yu, Shun-chieh; Huang, Shin-chung; Ho, Shao-lun; Yeh, Ming-lun; Wang, Chih-wen; Liang, Po-cheng; Wei, Yu-ju; Hsu, Po-yao; Huang, Ching-i; Hsieh, Ming-yen; Lin, Yi-hung; Yu, Sung-lin; Wu, Pey-fang; Chen, Yu-han; Chien, Shin-chi; Huang, Jee-fu; Dai, Chia-yen; Chuang, Wan-long; Wang, Tso-jen; Yu, Ming-lung; | 書刊名 | The Kaohsiung Journal of Medical Sciences |
卷 期 | 40:1 2024.01[民113.01] |
頁 次 | 頁86-93 |
分類號 | 419.82 |
關鍵詞 | HCV; Microelimination; Outreach; Psychiatric disease; Schizophrenia; |
語 文 | 英文(English) |
DOI | 10.1002/kjm2.12780 |
英文摘要 | Patients with serious mental illness have a higher risk of hepatitis C virus (HCV) infec- tion but suboptimal HCV care. The current study aimed to facilitate HCV treatment uptake by implementing an integrated outreach care model. Multidisciplinary out- reach screening followed by HCV reflex testing and onsite treatment for schizophre- nia patients was accomplished through the coordination of nongovernmental organizations, remote specialists, and local care providers. The objective was microeli- mination effectiveness, defined as the multiplication of the rates of anti-HCV anti- bodies screening, accurate HCV RNA diagnosis, treatment allocation, treatment completion, and sustained virological response (SVR12; no detectable HCV RNA throughout 12 weeks in the post-treatment follow-up period). A total of 1478 of the 2300 (64.3%) psychiatric patients received HCV mass screening. Seventy-three (4.9%) individuals were seropositive for anti-HCV antibodies. Of the 73 anti-HCV seropositive patients, all (100%) received HCV reflex testing, and 29 (37.7%) patients had HCV viremia. Eight patients (34.8%) had advanced liver disease, including 3 with liver cirrhosis and 2 with newly diagnosed hepatocellular carcinoma. Twenty-three of the 24 (95.8%) patients who stayed in the healthcare system received and completed 8 weeks of glecaprevir/pibrentasvir treatment and post-treatment follow-up without significant DDIs or adverse events. The SVR12 rate was 100%. The microelimination effectiveness in the current study was 61.6%. Individuals with serious mental illness are underserved and suffer from diagnostic delays. This patient-centered and inte- grated outreach program facilitated HCV care in this marginalized population. |
本系統中英文摘要資訊取自各篇刊載內容。